Safety of tranexamic acid (TXA), even at higher doses, was upheld in a meta-analysis.
Across 216 randomized trials in various medical disciplines, the incidence of thromboembolic events including venous thrombosis, pulmonary embolism, venous thromboembolism, myocardial infarction (MI) or ischemia, and cerebral infarction or ischemia reached 2.1% of people receiving IV TXA and a similar 2.0% of peers getting placebo or another control (
P=0.49).
However, safety of TXA was inconclusive for the subgroup of people with neurological conditions, who showed increased heterogeneity and asymmetry in funnel plots, according to Patrick Meybohm, MD, of University Hospital Wuerzburg in Germany, and colleagues in
Administration of TXA was associated with a significant reduction in overall mortality and bleeding mortality, but not nonbleeding mortality.